FindTrial
Sign In

Does buprenorfine added to an femoral blockade increase pain blockade after total knee replacement?

Does buprenorphine (Temgesic) 0,3 mg prolongs the analgesic effect of a blockade of the femoral nerve with 20 ml ropivacaïne HCL Fresenius Kabi 0,2% for patiënts with a total knee replacement. A prospective tripple blinded, single center, placebo controlled RCT - Buprenorfine, nervus femoralis, ropivacaïne, total knee replacement

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2013-002449-12-NL
Enrollment
Unknown
Registered
2013-08-16
Start date
2013-11-19
Completion date
Unknown
Last updated
2013-11-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Trade Name: Temgesic Product Name: buprenorfinehydrochloride Pharmaceutical Form: Solution for injection INN or Proposed INN: Buprenorphine CAS Number: 53152-21-9 Other descriptive name: BUPRENORPHINE

Sponsors

Westfriesgasthuis
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: - Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 20 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 55

Exclusion criteria

Exclusion criteria: -

Design outcomes

Primary

MeasureTime frame
Main Objective: -;Secondary Objective: -;Primary end point(s): -;Timepoint(s) of evaluation of this end point: -—

Secondary

MeasureTime frame
Secondary end point(s): -;Timepoint(s) of evaluation of this end point: -—

Countries

Netherlands

Contacts

Public ContactH. Zonneveldt

Westfriesgasthuis

H.Zonneveldt@westfriesgasthuis.nl0031229208562

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026